Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy.
Allografts
Animals
Antigens, CD19
/ immunology
CRISPR-Cas Systems
Cells, Cultured
Disease Models, Animal
Histocompatibility Antigens Class I
/ chemistry
Histocompatibility Antigens Class II
/ chemistry
Humans
Immunotherapy, Adoptive
/ methods
Leukocytes, Mononuclear
Lymphocyte Activation
Mice
Mice, Inbred NOD
Mice, SCID
Neoplasms
/ immunology
Receptors, Antigen, T-Cell
/ antagonists & inhibitors
Receptors, Chimeric Antigen
/ immunology
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
27
07
2018
revised:
08
03
2019
accepted:
16
04
2020
pubmed:
24
4
2020
medline:
16
1
2021
entrez:
24
4
2020
Statut:
ppublish
Résumé
Adoptive immunotherapy can induce sustained therapeutic effects in some cancers. Antitumor T-cell grafts are often individually prepared
Identifiants
pubmed: 32321775
pii: 2326-6066.CIR-18-0508
doi: 10.1158/2326-6066.CIR-18-0508
doi:
Substances chimiques
Antigens, CD19
0
Histocompatibility Antigens Class I
0
Histocompatibility Antigens Class II
0
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
926-936Informations de copyright
©2020 American Association for Cancer Research.